<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xml:lang="EN" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?origin publisher?><?properties no_embargo?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neural Transm</journal-id><journal-title>Journal of Neural Transmission</journal-title><issn pub-type="ppub">0300-9564</issn><issn pub-type="epub">1435-1463</issn><publisher><publisher-name>Springer Vienna</publisher-name><publisher-loc>Vienna</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">224</article-id><article-id pub-id-type="doi">10.1007/s00702-009-0224-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Dementias - Original Article</subject></subj-group></article-categories><title-group><article-title>Circulating immune complexes of A&#x003b2; and IgM in plasma of patients with Alzheimer&#x02019;s disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Marcello</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wirths</surname><given-names>Oliver</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schneider-Axmann</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Degerman-Gunnarsson</surname><given-names>Malin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lannfelt</surname><given-names>Lars</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Bayer</surname><given-names>Thomas A.</given-names></name><address><phone>+49-551-3922912</phone><fax>+49-551-3910291</fax><email>tbayer@gwdg.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>Department of Psychiatry, University Medicine Goettingen, G&#x000f6;ttingen, Germany </aff><aff id="Aff2"><label>2</label>Department of Public Health and Geriatrics, Uppsala University Hospital, Uppsala, Sweden </aff><aff id="Aff3"><label>3</label>Division of Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University Medicine Goettingen, von-Siebold-Strasse 5, 37075 G&#x000f6;ttingen, Germany </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>5</month><year>2009</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2009</year></pub-date><volume>116</volume><issue>7</issue><fpage>913</fpage><lpage>920</lpage><history><date date-type="received"><day>23</day><month>1</month><year>2009</year></date><date date-type="accepted"><day>21</day><month>3</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2009</copyright-statement></permissions><abstract xml:lang="EN"><p>It has previously been shown that immune complexes (IC) of a given biomarker with class M immunoglobulins (IgM) provide better performances compared to the unbound biomarker in a number of cancer entities. In the present work, we investigated IC of IgM-A&#x003b2; as a potential biomarker for Alzheimer&#x02019;s disease (AD). A&#x003b2;&#x02013;IgM concentration has been measured in 75 plasma samples from patients with AD, individuals with mild cognitive impairment (MCI), and healthy age- and sex-matched controls (HC). To characterize the fractions associated with A&#x003b2;, pooled plasma samples were subjected to gel-filtration analysis. Size-separated fractions were analyzed for the presence of A&#x003b2; using a sandwich ELISA assay. A strong reactivity was observed in the high molecular weight IgM (&#x0003e;500&#x000a0;kDa) and 150&#x000a0;kDa (IgG) fractions indicating that blood A&#x003b2; is strongly associated with antibodies. Using an ELISA assay detecting A&#x003b2;&#x02013;IgM complexes, we observed that high levels of A&#x003b2;&#x02013;IgMs were detectable in HC and MCI patients; however, there was no significant difference to the AD group.</p></abstract><kwd-group><title>Keywords</title><kwd>Alzheimer&#x02019;s disease</kwd><kwd>Immune complexes</kwd><kwd>A&#x003b2;</kwd><kwd>Biomarkers</kwd><kwd>Plasma</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2009</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>The earliest pathological events leading to Alzheimer&#x02019;s disease (AD) are estimated to occur 10&#x02013;20&#x000a0;years before the appearance of the first cognitive changes in affected patients (Price and Morris <xref ref-type="bibr" rid="CR43">1999</xref>; Yamaguchi et al. <xref ref-type="bibr" rid="CR59">2001</xref>). Therefore, identification of biomarkers predictive for AD might allow screening for individuals who may benefit from preventive therapies before the development of cognitive impairment. The A&#x003b2;42 peptide is supposed to have a central role in the pathogenesis of AD (Hardy and Selkoe <xref ref-type="bibr" rid="CR21">2002</xref>), and its measurement in the cerebrospinal fluid (CSF) became nowadays a routine diagnostic procedure with 75&#x02013;95% sensitivity and specificity (Blennow <xref ref-type="bibr" rid="CR8">2004</xref>; Jensen et al. <xref ref-type="bibr" rid="CR24">1999</xref>; Lewczuk et al. <xref ref-type="bibr" rid="CR31">2004</xref>). Unfortunately, CSF and blood levels of A&#x003b2; do not correlate, neither in AD patients (Mehta et al. <xref ref-type="bibr" rid="CR38">2001</xref>) nor in healthy controls (Mehta and Pirttila <xref ref-type="bibr" rid="CR36">2005</xref>). On the other side, it has been also shown that there is a correlation between CSF and plasma levels of A&#x003b2;40 and A&#x003b2;42 in healthy individuals, whereas no such correlation could be seen for AD or MCI cases (Giedraitis et al. <xref ref-type="bibr" rid="CR17">2007</xref>).</p><p>Studies on plasma A&#x003b2; levels have shown contradictory results, ranging from increased A&#x003b2;40 and decreased A&#x003b2;42 in AD patients compared to healthy controls (Xu and Gaskin <xref ref-type="bibr" rid="CR58">2008</xref>), no differences (Fukumoto et al. <xref ref-type="bibr" rid="CR14">2003</xref>; Vanderstichele et al. <xref ref-type="bibr" rid="CR53">2000</xref>) or increased A&#x003b2;42 in AD patients (Matsubara et al. <xref ref-type="bibr" rid="CR32">1999</xref>). The different findings in these studies may be due to differences in study designs, including variations in age and disease severity of included subjects. A longitudinal study showed that plasma A&#x003b2;40 and A&#x003b2;42 levels measured at age 70&#x000a0;years were not significantly associated with incident AD (Sundelof et al. <xref ref-type="bibr" rid="CR45">2008</xref>). All of the studies though, have shown substantial overlap in plasma A&#x003b2;40 and A&#x003b2;42 levels between patients and controls, thus limiting the diagnostic value of plasma A&#x003b2; assessment. Although the significance of A&#x003b2; for diagnosing Alzheimer&#x02019;s disease is controversial, high plasma concentrations of A&#x003b2;40 and low plasma concentrations of A&#x003b2;42 indicate an increased risk of dementia (reviewed in Kawarabayashi and Shoji <xref ref-type="bibr" rid="CR26">2008</xref>). Nonetheless, analysis of plasma instead of CSF would be highly desirable because of its better accessibility and less invasive sampling procedure. Plasma A&#x003b2; levels are commonly quantified with enzyme-linked immunoabsorbent assays (ELISA) using antibodies against a variety of A&#x003b2; epitopes (for example Mehta et al. <xref ref-type="bibr" rid="CR37">2000</xref>; Suzuki et al. <xref ref-type="bibr" rid="CR46">1994</xref>). Quantification of A&#x003b2; in blood is technically difficult and limited by the fact that most of it is bound to blood components, including lipids serum albumin, &#x003b1;2-macroglobulin, immunoglobulins, apolipoprotein J, transthyritin, apoferritin, as well as complement components C1q and C3 (Biere et al. <xref ref-type="bibr" rid="CR7">1996</xref>; Kuo et al. <xref ref-type="bibr" rid="CR29">2000</xref>).</p><p>Besides the detection of biochemical AD markers, autoimmune responses to molecules specific to AD pathology have become a current research focus (Gruden et al. <xref ref-type="bibr" rid="CR19">2004</xref>; Nath et al. <xref ref-type="bibr" rid="CR39">2003</xref>). There seems to be a reduction in the magnitude of lymphocyte stimulation by APP in AD patients (Trieb et al. <xref ref-type="bibr" rid="CR50">1996</xref>), and naturally occurring anti-A&#x003b2; antibodies seem to be present in sera and CSF of AD patients and healthy controls (Du et al. <xref ref-type="bibr" rid="CR13">2001</xref>). However, whether autoimmunity plays a direct role in the pathogenesis of AD is still open to debate (McGeer and McGeer <xref ref-type="bibr" rid="CR34">2001</xref>; Singh <xref ref-type="bibr" rid="CR44">1997</xref>; Tarkowski et al. <xref ref-type="bibr" rid="CR49">2003</xref>).</p><p>In the present study, the level of circulating immune complexes (ICs) between A&#x003b2; and class M immunoglobulins (IgM) has been investigated, because ICs have been shown to be relevant biomarkers for different types of cancers (Beneduce et al. <xref ref-type="bibr" rid="CR4">2005</xref>, 2006; Castaldi et al. <xref ref-type="bibr" rid="CR9">2005</xref>), showing an improved diagnostic power compared to the free biomarker protein.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Patients and samples</title><p>Plasma samples (stored at &#x02212;70&#x000b0;C) from 30 out-patients with mild to moderate AD, 15 patients with mild cognitive impairment (MCI) and 30 healthy controls (HC) were analyzed. The patients were recruited at the Memory Clinic at the Department of Geriatrics, Uppsala University Hospital. All AD patients were diagnosed according to DSM IV (American Psychiatric Association <xref ref-type="bibr" rid="CR1">2000</xref>) and NINCDS-ADRDA (McKhann et al. <xref ref-type="bibr" rid="CR35">1984</xref>). The MCI patients met the Petersen criteria (Winblad et al. <xref ref-type="bibr" rid="CR55">2004</xref>) for MCI.</p></sec><sec id="Sec4"><title>Gel filtration</title><p>Plasma samples from five AD patients and five healthy controls showing high reactivity to A&#x003b2;&#x02013;IgM immune complexes in a preliminary assay were grouped and analyzed by gel-filtration HPLC. 500&#x000a0;&#x000b5;l of pooled samples were analyzed using a gel-filtration column Superdex 200 10/300 GL (GE Healthcare, Freiburg, Germany) on an ACTA Basic system (GE Healthcare, Freiburg, Germany). The elution was carried out in PBS at a flow rate of 1&#x000a0;ml per minute, and sample absorbance was monitored at 280&#x000a0;nm. Fractions were collected every 30&#x000a0;s, immunoreactivity was tested by ELISA and the fractions corresponding to the highest immunoreactivity were pooled and used as reference standard. Before running the samples, a calibration run was carried out according to the manufacturer&#x02019;s instructions.</p></sec><sec id="Sec5"><title>ELISA assay to detect A&#x003b2;</title><p>The A&#x003b2; level in gel-filtration fractions was determined as follows: 96-well ELISA plates were coated with 50&#x000a0;&#x003bc;l per well of 1&#x000a0;&#x003bc;g/ml of mouse anti-human A&#x003b2; antibody directed against residues 17-24 (4G8, Signet Laboratories, Dedham, MA, USA) in PBS at 4&#x000b0;C overnight and then blocked for 2&#x000a0;h with 3% BSA in PBS at 37&#x000b0;C. After blocking, 50&#x000a0;&#x003bc;l of gel-filtration fractions in PBS containing 1% BSA and 0.05% Tween 20 (PBS-B-T) were incubated for 1.5&#x000a0;h at 37&#x000b0;C. The wells were then washed with PBS containing 0.05% Tween 20 and incubated with 50&#x000a0;&#x003bc;l of rabbit polyclonal anti-A&#x003b2; 692 (generous gift from Gerd Multhaup, Free University of Berlin) at a 1:1,000 dilution in PBS-B-T for 1.5&#x000a0;h at 37&#x000b0;C. A&#x003b2; was revealed using peroxidase-conjugated goat anti-rabbit IgG (Dako, Glostrup, Denmark) in a 1:1,000 dilution in PBS-B-T and developed with TMB (Pierce manufacturing, Appleton, IL, USA) and hydrogen peroxide as substrate. The results of A&#x003b2; determination in the gel-filtration fractions were reported in optical density.</p></sec><sec id="Sec6"><title>ELISA assay to detect A&#x003b2;&#x02013;IgM immune complexes</title><p>96-well ELISA plates were coated with 50&#x000a0;&#x003bc;L per well of 1&#x000a0;&#x003bc;g/mL 4G8 antibody (Signet Laboratories, Dedham, MA, USA) in PBS at 4&#x000b0;C overnight and then blocked for 2&#x000a0;h with 3% BSA in PBS. After blocking, 50&#x000a0;&#x003bc;l of serially diluted reference standard or samples in PBS-B-T were incubated for 1.5&#x000a0;h at 37&#x000b0;C. The A&#x003b2;&#x02013;IgM complex was revealed using peroxidase-conjugated anti-human IgM (Sigma-Aldrich, Munich, Germany) at a dilution of 1:3,000 in PBS-B-T and developed with TMB and hydrogen peroxide as the substrate. A&#x003b2;&#x02013;IgM IC levels in the plasma were expressed in arbitrary units/ml (AU/ml) by using gel-filtration-purified A&#x003b2;&#x02013;IgM reference standards to design a calibration curve, where the undiluted standard was assigned 1,000&#x000a0;AU/ml; concentration was determined by interpolation of samples absorbance on the calibration curve. The linear range of the assay was between 3.9 and 62.5&#x000a0;AU/ml. The samples with values above 62.5&#x000a0;AU/ml were further diluted and re-measured. The assay was standardized and its analytical performance evaluated: inter- and intra-assay coefficient of variation (CV) was less than 10%. A&#x003b2;&#x02013;IgM cut-off was selected as the best combination of specificity and sensitivity according to the receiver-operating characteristic (ROC) curve.</p></sec><sec id="Sec7"><title>Western blot</title><p>Gel-filtration fractions corresponding to 280&#x000a0;nm absorbance peaks were separated on a 4&#x02013;12% variogel (Anamed, Gro&#x000df;-Bieberau, Germany) and then transferred to a nitrocellulose membrane. The membrane was heated in PBS in a microwave for 5&#x000a0;min and then blocked in 10% non-fat dry milk in TBS containing 0.05% Tween (TBS-T) for 1&#x000a0;h at room temperature. Blots were then incubated with peroxidase-conjugated goat anti-human IgM (Sigma-Aldrich) at 1:1,000 in TBS-T for 2&#x000a0;h or, alternatively, with a primary antibody directed against A&#x003b2; residues 4-10 (W0-2, The Genetics Company, Switzerland) overnight at 4&#x000b0;C and secondary peroxidase-conjugated antibodies for 2&#x000a0;h at room temperature. Protein bands were revealed using chemiluminescence solution and peroxide hydrogen as substrates on a Curix60 developing machine (Agfa-Gevaert N.V., Mortsel, Belgium).</p></sec><sec id="Sec8"><title>Data analysis</title><p>All biomarker values were expressed as mean values&#x000a0;&#x000b1;&#x000a0;standard deviation. Differences between the groups were determined by ANOVA followed by Student <italic>t</italic> tests. The diagnostic powers were determined by ROC curve analysis. Chi-square test on independence was used to analyze, if the gender distribution was significantly different between the three groups and if there is a difference between the two patient groups in relation to the number of family members with dementia. All analyses were performed using GraphPad Prism (GraphPad software, Inc., La Jolla, CA, USA and SPSS 16 for Windows). Significance level was &#x003b1;&#x000a0;=&#x000a0;0.05. All tests were two-tailed.</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><p>There were no significant age differences between the three groups [Alzheimer patients (AD), MCI and healthy controls] (<italic>F</italic>&#x000a0;=&#x000a0;0.3, <italic>df</italic>&#x000a0;=&#x000a0;2, 72; <italic>P</italic>&#x000a0;=&#x000a0;0.74). Patients with MCI diagnosis were not significantly older at onset of the disease than AD patients (<italic>F</italic>&#x000a0;=&#x000a0;2.3, <italic>df</italic>&#x000a0;=&#x000a0;1, 42; <italic>P</italic>&#x000a0;=&#x000a0;0.13). As expected, the mean MMSE score was higher in MCI compared to AD patients (<italic>F</italic>&#x000a0;=&#x000a0;44.3, <italic>df</italic>&#x000a0;=&#x000a0;1, 40; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0005). Gender distribution was not significantly different between the three groups (Chi&#x000b2;&#x000a0;=&#x000a0;1.2, <italic>df</italic>&#x000a0;=&#x000a0;2; <italic>P</italic>&#x000a0;=&#x000a0;0.55) and the proportion of family members with dementia did not differ significantly between the two patients groups (Chi&#x000b2;&#x000a0;=&#x000a0;0.8, <italic>df</italic>&#x000a0;=&#x000a0;1; <italic>P</italic>&#x000a0;=&#x000a0;0.38) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Demographic data of the studied groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="2">AD</th><th align="left" colspan="2">MCI</th><th align="left" colspan="2">HC</th><th align="left">Chi<sup>2</sup></th><th align="left"><italic>df</italic></th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">Gender (male, female)</td><td align="left" colspan="2">M: 12, F: 18</td><td align="left" colspan="2">M: 8, F: 7</td><td align="left" colspan="2">M:11, F: 19</td><td char="." align="char">1.2</td><td align="left">2</td><td char="." align="char">0.55</td></tr><tr><td align="left">Dementia in family</td><td align="left" colspan="2">Yes: 16, no: 12</td><td align="left" colspan="2">Yes: 6, no: 8</td><td align="left" colspan="2"/><td char="." align="char">0.8</td><td align="left">1</td><td char="." align="char">0.38</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><italic>n</italic></th><th align="left">m&#x000a0;&#x000b1;&#x000a0;SD</th><th align="left"><italic>n</italic></th><th align="left">m&#x000a0;&#x000b1;&#x000a0;SD</th><th align="left"><italic>n</italic></th><th align="left">m&#x000a0;&#x000b1;&#x000a0;SD</th><th align="left"><italic>F</italic></th><th align="left"><italic>df</italic></th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left">30</td><td char="&#x000b1;" align="char">72.3&#x000a0;&#x000b1;&#x000a0;6.7</td><td char="&#x000b1;" align="char">15</td><td char="&#x000b1;" align="char">73.7&#x000a0;&#x000b1;&#x000a0;4.3</td><td align="left">30</td><td align="left">72.5&#x000a0;&#x000b1;&#x000a0;5.2</td><td char="." align="char">0.3</td><td align="left">2, 72</td><td char="." align="char">0.74</td></tr><tr><td align="left">Age at onset (years)</td><td align="left">30</td><td char="&#x000b1;" align="char">67.9&#x000a0;&#x000b1;&#x000a0;7.9</td><td char="&#x000b1;" align="char">14</td><td char="&#x000b1;" align="char">71.4&#x000a0;&#x000b1;&#x000a0;4.9</td><td align="left"/><td align="left"/><td char="." align="char">2.3</td><td align="left">1, 42</td><td char="." align="char">0.13</td></tr><tr><td align="left">MMSE (at screening)</td><td align="left">27</td><td char="&#x000b1;" align="char">17.3&#x000a0;&#x000b1;&#x000a0;6.1</td><td char="&#x000b1;" align="char">15</td><td char="&#x000b1;" align="char">27.9&#x000a0;&#x000b1;&#x000a0;1.3</td><td align="left"/><td align="left"/><td char="." align="char">44.3</td><td align="left">1, 40</td><td char="." align="char">&#x0003c;0.0005</td></tr></tbody></table><table-wrap-foot><p><italic>AD</italic> Alzheimer&#x02019;s disease, <italic>MCI</italic> mild cognitive impaired individuals, <italic>HC</italic> healthy controls, <italic>m</italic> mean, <italic>SD</italic> standard deviation, <italic>Chi</italic><sup><italic>2</italic></sup> Chi-square statistic, <italic>F</italic> F-statistic, <italic>df</italic> degrees of freedom, <italic>P</italic> probability, <italic>M</italic> male, <italic>F</italic> female</p></table-wrap-foot></table-wrap></p><p>In order to identify circulating A&#x003b2;&#x02013;IgM complexes, plasma samples from ten individuals were pooled and analyzed by gel filtration. Fractions collected from the column were tested for the presence of generic A&#x003b2; and A&#x003b2;&#x02013;IgM complexes using ELISA assays. A strong immunoreactivity against A&#x003b2; was observed in the fraction eluting at high molecular weight (&#x0003e;500&#x000a0;kDa) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). In the same fraction high reactivity for ICs of A&#x003b2; with IgM was also found, thus providing the first evidence of the occurrence of circulating A&#x003b2;&#x02013;IgM complexes (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c). Reactivity for generic A&#x003b2; was also found in the fractions eluting at 150&#x000a0;kDa (IgG fraction) and at low molecular weight (not shown). Reactivity against the monomeric form of A&#x003b2; has been found in all fractions, confirming previous observations (Kuo et al. <xref ref-type="bibr" rid="CR30">2000</xref>). The fractions contained components migrating at the expected molecular weight for reduced IgM that were stained by antihuman IgM antibodies (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p><bold>a</bold> Gel-filtration HPLC of pooled plasma samples. Proteins are separated according to their molecular weight, with the larger proteins eluting first. Total protein concentration of each fraction was measured at 280&#x000a0;nm (<italic>gray line</italic>). The characteristic peaks were as follows: empty volume with a MW&#x000a0;&#x0003e;&#x000a0;500&#x000a0;kDa (IgMs), IgGs with a MW of ~150&#x000a0;kDa, and the albumin peak at ~66&#x000a0;kDa. A direct ELISA performed on each fraction to measure the quantity of generic A&#x003b2; (<italic>diamonds</italic>) shows that most of A&#x003b2; elutes in the empty volume and IgG fractions suggesting that A&#x003b2; in the blood is strongly associated with antibodies. <bold>b</bold> Western blot against A&#x003b2; in the empty volume (<italic>IgM</italic>) fraction and IgM showing the presence of A&#x003b2; in the IgM fraction</p></caption><graphic position="anchor" xlink:href="702_2009_224_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p><bold>a</bold> Sandwich ELISA. 96-well titer plates are coated with anti-A&#x003b2; (4G8). After incubation with plasma samples, the wells are washed and incubated with an anti-IgM heavy chain antibody conjugated with HRP. Signal of bound molecules is therefore only produced by complexes of both IgM and antigen. <bold>b</bold> Calibration curve obtained by serial dilutions of the IgM fraction. <bold>c</bold> A&#x003b2;-IgM (<italic>diamonds</italic>) immune complexes in the fractions derived from gel-filtration HPLC compared to total protein concentration (<italic>solid line</italic>)</p></caption><graphic position="anchor" xlink:href="702_2009_224_Fig2_HTML" id="MO2"/></fig></p><p>To assess the relevance of these findings, plasma samples from 75 patients with AD, MCI, and from healthy donors were analyzed for the presence of A&#x003b2;&#x02013;IgM ICs. Serial dilutions of the gel filtration-purified IC fraction have been used to draw a reference calibration curve. By interpolation with the standard curve, A&#x003b2;&#x02013;IgM IC concentration in the plasma samples has been expressed in arbitrary units (AU)/ml. According to ANOVA test, no significant differences among the three diagnostic groups were observed (Student <italic>t</italic> test <italic>P</italic> value AD vs. HC&#x000a0;=&#x000a0;0.18, AD vs. MCI&#x000a0;=&#x000a0;0.61, MCI vs. HC&#x000a0;=&#x000a0;0.10) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Analysis of A&#x003b2;&#x02013;IgM immune complexes. <bold>a</bold> Levels of A&#x003b2;&#x02013;IgM immune complexes in the different diagnostic groups. <bold>b</bold> The comparison of the mean values do not show any significant difference. <bold>c</bold> ROC curve analysis shows a certain difference in the distribution of the immune complexes plasma concentration between AD and HC groups, which however was not significant</p></caption><graphic position="anchor" xlink:href="702_2009_224_Fig3_HTML" id="MO3"/></fig></p><p>ROC curve analysis showed that specificity was only 46.67% when sensitivity was set at 80%, and by setting specificity above 80%, sensitivity was 26.67% (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Comparison of specificity, sensitivity, positive predictive value (PPV&#x000a0;=&#x000a0;true positive (TP)/TP&#x000a0;+&#x000a0;false positive), negative predictive value (NPV&#x000a0;=&#x000a0;true negative (TN)/TN&#x000a0;+&#x000a0;false negative) of A&#x003b2;-IgM comparing AD patients with the healthy control (HC) group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Biomarker</th><th align="left">Cut-off (AU/mL)</th><th align="left">Sensitivity</th><th align="left">Specificity</th><th align="left">PPV</th><th align="left">NPV</th></tr></thead><tbody><tr><td align="left" rowspan="2">A&#x003b2;-IgM</td><td align="left">&#x0003c;1926</td><td align="left">80% (24/30)</td><td align="left">46.67% (16/30)</td><td align="left">60%</td><td align="left">70%</td></tr><tr><td align="left">&#x0003c;648.5</td><td align="left">26.67% (8/30)</td><td align="left">80% (6/30)</td><td align="left">57%</td><td align="left">52%</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec10" sec-type="discussion"><title>Discussion</title><p>The aim of the present study was to analyze the serological profile of samples from AD and MCI patients, and healthy controls, regarding the levels of A&#x003b2;&#x02013;IgM complexes, and to evaluate a possible correlation between the immunological profiles of individuals with AD. Immune complexes, in fact, have recently been proven to correlate better than unbound biomarkers with pathology in different cancer entities (Beneduce et al. <xref ref-type="bibr" rid="CR4"> 2005</xref>, <xref ref-type="bibr" rid="CR5">2007</xref>, <xref ref-type="bibr" rid="CR6">2008</xref>; Castaldi et al. <xref ref-type="bibr" rid="CR9">2005</xref>), which are characterized by an over- or mis-production of an endogenous protein. At present, only CSF A&#x003b2;42 levels is a well established A&#x003b2;-related AD biomarker with high sensitivity and specificity (Andreasen et al. <xref ref-type="bibr" rid="CR2">2001</xref>; Galasko et al. <xref ref-type="bibr" rid="CR15">1998</xref>; Kanai et al. <xref ref-type="bibr" rid="CR25">1998</xref>; Lewczuk et al. <xref ref-type="bibr" rid="CR31">2004</xref>; Tapiola et al. <xref ref-type="bibr" rid="CR48">2000</xref>). Unfortunately, there seems to be no correlation between CSF and blood A&#x003b2; level, as shown by several groups (Matsumoto et al. <xref ref-type="bibr" rid="CR33">2007</xref>; Mehta et al. <xref ref-type="bibr" rid="CR37">2000</xref>, <xref ref-type="bibr" rid="CR38">2001</xref>; Vanderstichele et al. <xref ref-type="bibr" rid="CR53">2000</xref>). A longitudinal study showed that CSF A&#x003b2;42 decreases within 12&#x000a0;months significantly in AD patients, while Tau and Phospho-Tau did not (Kessler et al. <xref ref-type="bibr" rid="CR27">2008</xref>). Although much better for clinical practice, blood-based A&#x003b2; levels are controversially discussed as a useful biomarker for AD. Studies have shown a decreased level of A&#x003b2; in AD subjects (Pesaresi et al. <xref ref-type="bibr" rid="CR41">2006</xref>; Xu and Gaskin <xref ref-type="bibr" rid="CR58">2008</xref>), while others showed an increase of A&#x003b2; concentration in the plasma of AD patients (Kosaka et al. <xref ref-type="bibr" rid="CR28">1997</xref>; Matsubara et al. <xref ref-type="bibr" rid="CR32">1999</xref>), or no statistical differences (Fukumoto et al. <xref ref-type="bibr" rid="CR14">2003</xref>; Tamaoka et al. <xref ref-type="bibr" rid="CR47">1996</xref>). The same inconsistency emerged from a series of prospective studies, in which a higher risk for developing AD has been associated both with higher baseline plasma A&#x003b2;42 concentration (Pomara et al. <xref ref-type="bibr" rid="CR42">2005</xref>) or higher A&#x003b2;40 with no effect on A&#x003b2;42 (van Oijen et al. <xref ref-type="bibr" rid="CR52">2006</xref>). Finally, Graff-Radford et al. (<xref ref-type="bibr" rid="CR18">2007</xref>) linked a high risk for developing AD to a lower A&#x003b2;42/40 ratio. Plasma anti-A&#x003b2; autoantibody concentration has also been investigated by several groups. Titers of anti-A&#x003b2;42 autoantibodies were reported to be lower in AD patients compared to healthy individuals (Du et al. <xref ref-type="bibr" rid="CR13">2001</xref>; Weksler et al. <xref ref-type="bibr" rid="CR54">2002</xref>), or higher in AD patients (Nath et al. <xref ref-type="bibr" rid="CR39">2003</xref>). One study reported no correlation between autoantibodies titers and plasma A&#x003b2;40 or 42 levels (Hyman et al. <xref ref-type="bibr" rid="CR23">2001</xref>).</p><p>The initial goal of this study was to characterize the occurrence of ICs of A&#x003b2; in the plasma of AD and MCI patients and HC, as seen with many cancer biomarkers. It is well known that IgM complexes are in equilibrium in blood with the unbound respective antigen and are used as reliable blood biomarkers for diagnosis of different cancer entities. It would make sense that the same equilibrium holds true for any IgM complex in blood. Already established immune complexes as biomarkers include: PSA&#x02013;IgM for prostate cancer (Beneduce et al. <xref ref-type="bibr" rid="CR5">2007</xref>), carcinoembryonic antigen&#x02013;IgM for colorectal cancer (Castaldi et al. <xref ref-type="bibr" rid="CR10">2005</xref>) alpha fetoprotein&#x02013;IgM and squamous cell carcinoma antigen-IgM for liver cancer (Beneduce et al. <xref ref-type="bibr" rid="CR3"> 2004</xref>, <xref ref-type="bibr" rid="CR4">2005</xref>). Moreover, IgM immune complexes have also been shown to be uncorrelated with basal IgM levels (Beneduce <xref ref-type="bibr" rid="CR6">2008</xref>). Nydegger (<xref ref-type="bibr" rid="CR40">2007</xref>) discussed in a review article biochemical properties of immune complexes in general, their formation and their equilibrium state, stating that immune complex interaction is extremely high compared to other biochemical interactions.</p><p>Plasma samples from 30 AD patients, 15 MCI patients, and 30 age- and sex-matched HC have been analyzed to determine the levels of circulating A&#x003b2;&#x02013;IgM ICs. After gel-filtration and size fractionation, A&#x003b2; was primarily found to be associated with the IgM and the IgG fractions using an ELISA. This is the first characterization of circulating A&#x003b2;&#x02013;IgM complexes in AD. The A&#x003b2;&#x02013;IgM assay did not show any significant difference among the three groups, in contrast with previous findings (Gruden et al. <xref ref-type="bibr" rid="CR20">2007</xref>), proving that although there is great interest around autoimmunity in AD, IC levels cannot be used as a diagnostic marker. It should be noted, however, that variability of IC level was high within the groups. This high variance leading to an overlap between AD patients and healthy controls might be partly due to biological variability. Consensus criteria for a suitable biomarker (Trojanowski et al. <xref ref-type="bibr" rid="CR51">1998</xref>) for AD were however not met.</p><p>On the other hand, the presence of circulating ICs against neuronal antigens supports the notion that autoimmune-mediated processes may be involved in neurodegenerative disorders. Further investigations are needed to elucidate the pathophysiological role of these complexes and the significance of autoantibodies in AD in general. Whether their role is neuroprotective or neurotoxic is still unknown. They may be seen both as a possible protective factor for AD, or as a risk factor in case of an unbalanced level. In any case, autoimmunity-driven homeostasis is a natural process and its understanding may be useful in both diagnosing and treating AD; there are evidences for a therapeutic use of anti-A&#x003b2; antibodies as it is being shown by current experimental immunotherapeutic approaches. Hock et al. (<xref ref-type="bibr" rid="CR22">2003</xref>) showed that active immunization against aggregated A&#x003b2;42 led to a slower cognitive decline in a dose-dependent fashion; patients generating a higher titer of anti-A&#x003b2; antibodies performed better in cognitive test than patients who did not respond to the immunization protocol. The increase in antibody titer did not correspond to a decrease in A&#x003b2; blood levels. In contrast, significant changes were observed in serum and CSF of patients with AD after treatment with intravenous A&#x003b2; IgGs (Dodel et al. <xref ref-type="bibr" rid="CR12">2002</xref>).</p><p>The levels of A&#x003b2; autoantibodies of the IgG class for monitoring the effect of passive or active immunization in AD have already been evaluated by recent studies. It is speculative to discuss a possible role of A&#x003b2;&#x02013;IgM levels as a predictive indicator of immunotherapy efficacy. A possible hypothesis includes that they serve as a &#x0201c;buffering system&#x0201d; to keep free potential toxic endogenous peptides and proteins under homeostatic control and lead to their clearance (Gruden et al. <xref ref-type="bibr" rid="CR20">2007</xref>). Previous studies have shown the presence of anti-A&#x003b2; autoantibodies (Xu and Gaskin <xref ref-type="bibr" rid="CR57">1997</xref>) and circulating IC of A&#x003b2; and IgGs of different classes (Gruden et al. <xref ref-type="bibr" rid="CR19">2004</xref>). APP transgenic mice injected intravenously with monoclonal anti-A&#x003b2; antibody showed a rapid and massive increase of CNS-derived A&#x003b2; in the plasma suggesting that antibodies may participate in A&#x003b2; clearance from the brain (DeMattos et al. <xref ref-type="bibr" rid="CR11">2001</xref>). However, whether this immune activity is defensive or toxic is still a matter of debate (Geylis et al. <xref ref-type="bibr" rid="CR16">2005</xref>; Nath et al. <xref ref-type="bibr" rid="CR39">2003</xref>; Woulfe et al. <xref ref-type="bibr" rid="CR56">2002</xref>). It will be interesting to evaluate in future studies possible relationships of A&#x003b2;-IC levels with the clinical development of MCI patients, and with AD patients&#x02019; response to immune therapies.</p></sec></body><back><ack><p>The excellent technical help of Petra Tucholla is gratefully acknowledged. Financial support was provided by the European Commission, Marie Curie Early Stage Training, MEST-CT-2005-020013 (NEURAD), International Alzheimer Ph.D. Graduate School.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><citation citation-type="other">American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders&#x02014;DSM-IV, 4th edn. American Psychiatric Association, Washington</citation></ref><ref id="CR2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Davidsson</surname><given-names>P</given-names></name><name><surname>Vanmechelen</surname><given-names>E</given-names></name><etal/></person-group><article-title>Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice</article-title><source>Arch Neurol</source><year>2001</year><volume>58</volume><issue>3</issue><fpage>373</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1001/archneur.58.3.373</pub-id></citation><citation citation-type="display-unstructured">Andreasen N, Minthon L, Davidsson P, Vanmechelen E et al (2001) Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58(3):373&#x02013;379 <pub-id pub-id-type="pmid">11255440</pub-id></citation></ref><ref id="CR3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beneduce</surname><given-names>L</given-names></name><name><surname>Castaldi</surname><given-names>F</given-names></name><name><surname>Marino</surname><given-names>M</given-names></name><name><surname>Tono</surname><given-names>N</given-names></name><etal/></person-group><article-title>Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes</article-title><source>Int J Biol Markers</source><year>2004</year><volume>19</volume><issue>2</issue><fpage>155</fpage><lpage>159</lpage></citation><citation citation-type="display-unstructured">Beneduce L, Castaldi F, Marino M, Tono N et al (2004) Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes. Int J Biol Markers 19(2):155&#x02013;159 <pub-id pub-id-type="pmid">15255549</pub-id></citation></ref><ref id="CR4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beneduce</surname><given-names>L</given-names></name><name><surname>Castaldi</surname><given-names>F</given-names></name><name><surname>Marino</surname><given-names>M</given-names></name><name><surname>Quarta</surname><given-names>S</given-names></name><etal/></person-group><article-title>Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma</article-title><source>Cancer</source><year>2005</year><volume>103</volume><issue>12</issue><fpage>2558</fpage><lpage>2565</lpage><pub-id pub-id-type="doi">10.1002/cncr.21106</pub-id></citation><citation citation-type="display-unstructured">Beneduce L, Castaldi F, Marino M, Quarta S et al (2005) Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer 103(12):2558&#x02013;2565 <pub-id pub-id-type="pmid">15887222</pub-id></citation></ref><ref id="CR5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beneduce</surname><given-names>L</given-names></name><name><surname>Prayer-Galetti</surname><given-names>T</given-names></name><name><surname>Giustinian</surname><given-names>AM</given-names></name><name><surname>Gallotta</surname><given-names>A</given-names></name><etal/></person-group><article-title>Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients</article-title><source>Cancer Detect Prev</source><year>2007</year><volume>31</volume><issue>5</issue><fpage>402</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1016/j.cdp.2007.10.005</pub-id></citation><citation citation-type="display-unstructured">Beneduce L, Prayer-Galetti T, Giustinian AM, Gallotta A et al (2007) Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients. Cancer Detect Prev 31(5):402&#x02013;407 <pub-id pub-id-type="pmid">18035503</pub-id></citation></ref><ref id="CR6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beneduce</surname><given-names>L</given-names></name><name><surname>Pesce</surname><given-names>G</given-names></name><name><surname>Gallotta</surname><given-names>A</given-names></name><name><surname>Zampieri</surname><given-names>F</given-names></name><etal/></person-group><article-title>Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma</article-title><source>Eur J Clin Invest</source><year>2008</year><volume>38</volume><issue>8</issue><fpage>571</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2362.2008.01985.x</pub-id></citation><citation citation-type="display-unstructured">Beneduce L, Pesce G, Gallotta A, Zampieri F et al (2008) Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma. Eur J Clin Invest 38(8):571&#x02013;577 <pub-id pub-id-type="pmid">18625005</pub-id></citation></ref><ref id="CR7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Biere</surname><given-names>AL</given-names></name><name><surname>Ostaszewski</surname><given-names>B</given-names></name><name><surname>Stimson</surname><given-names>ER</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><etal/></person-group><article-title>Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><issue>51</issue><fpage>32916</fpage><lpage>32922</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.51.32916</pub-id></citation><citation citation-type="display-unstructured">Biere AL, Ostaszewski B, Stimson ER, Hyman BT et al (1996) Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 271(51):32916&#x02013;32922 <pub-id pub-id-type="pmid">8955133</pub-id></citation></ref><ref id="CR8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blennow</surname><given-names>K</given-names></name></person-group><article-title>Cerebrospinal fluid protein biomarkers for Alzheimer&#x02019;s disease</article-title><source>NeuroRx</source><year>2004</year><volume>1</volume><issue>2</issue><fpage>213</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1602/neurorx.1.2.213</pub-id></citation><citation citation-type="display-unstructured">Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimer&#x02019;s disease. NeuroRx 1(2):213&#x02013;225 <pub-id pub-id-type="pmid">15717022</pub-id></citation></ref><ref id="CR9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Castaldi</surname><given-names>F</given-names></name><name><surname>Marino</surname><given-names>M</given-names></name><name><surname>Beneduce</surname><given-names>L</given-names></name><name><surname>Belluco</surname><given-names>C</given-names></name><etal/></person-group><article-title>Detection of circulating CEA-IgM complexes in early stage colorectal cancer</article-title><source>Int J Biol Markers</source><year>2005</year><volume>20</volume><issue>4</issue><fpage>204</fpage><lpage>208</lpage></citation><citation citation-type="display-unstructured">Castaldi F, Marino M, Beneduce L, Belluco C et al (2005a) Detection of circulating CEA-IgM complexes in early stage colorectal cancer. Int J Biol Markers 20(4):204&#x02013;208 <pub-id pub-id-type="pmid">16398401</pub-id></citation></ref><ref id="CR10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Castaldi</surname><given-names>F</given-names></name><name><surname>Marino</surname><given-names>M</given-names></name><name><surname>Beneduce</surname><given-names>L</given-names></name><name><surname>Belluco</surname><given-names>C</given-names></name><etal/></person-group><article-title>Detection of circulating CEA-IgM complexes in early stage colorectal cancer Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma</article-title><source>Int J Biol Markers</source><year>2005</year><volume>20</volume><issue>4</issue><fpage>204</fpage><lpage>208</lpage></citation><citation citation-type="display-unstructured">Castaldi F, Marino M, Beneduce L, Belluco C et al (2005b) Detection of circulating CEA-IgM complexes in early stage colorectal cancer Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Int J Biol Markers 20(4):204&#x02013;208 <pub-id pub-id-type="pmid">16398401</pub-id></citation></ref><ref id="CR11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DeMattos</surname><given-names>RB</given-names></name><name><surname>Bales</surname><given-names>KR</given-names></name><name><surname>Cummins</surname><given-names>DJ</given-names></name><name><surname>Dodart</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer&#x02019;s disease</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><issue>15</issue><fpage>8850</fpage><lpage>8855</lpage><pub-id pub-id-type="doi">10.1073/pnas.151261398</pub-id></citation><citation citation-type="display-unstructured">DeMattos RB, Bales KR, Cummins DJ, Dodart JC et al (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer&#x02019;s disease. Proc Natl Acad Sci USA 98(15):8850&#x02013;8855 <pub-id pub-id-type="pmid">11438712</pub-id></citation></ref><ref id="CR12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dodel</surname><given-names>R</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Depboylu</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer&#x02019;s disease</article-title><source>Ann Neurol</source><year>2002</year><volume>52</volume><issue>2</issue><fpage>253</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1002/ana.10253</pub-id></citation><citation citation-type="display-unstructured">Dodel R, Hampel H, Depboylu C, Lin S et al (2002) Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer&#x02019;s disease. Ann Neurol 52(2):253&#x02013;256 <pub-id pub-id-type="pmid">12210803</pub-id></citation></ref><ref id="CR13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Dodel</surname><given-names>R</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Buerger</surname><given-names>K</given-names></name><etal/></person-group><article-title>Reduced levels of amyloid beta-peptide antibody in Alzheimer disease</article-title><source>Neurology</source><year>2001</year><volume>57</volume><issue>5</issue><fpage>801</fpage><lpage>805</lpage></citation><citation citation-type="display-unstructured">Du Y, Dodel R, Hampel H, Buerger K et al (2001) Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 57(5):801&#x02013;805 <pub-id pub-id-type="pmid">11552007</pub-id></citation></ref><ref id="CR14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fukumoto</surname><given-names>H</given-names></name><name><surname>Tennis</surname><given-names>M</given-names></name><name><surname>Locascio</surname><given-names>JJ</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><etal/></person-group><article-title>Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels</article-title><source>Arch Neurol</source><year>2003</year><volume>60</volume><issue>7</issue><fpage>958</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1001/archneur.60.7.958</pub-id></citation><citation citation-type="display-unstructured">Fukumoto H, Tennis M, Locascio JJ, Hyman BT et al (2003) Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 60(7):958&#x02013;964 <pub-id pub-id-type="pmid">12873852</pub-id></citation></ref><ref id="CR15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Motter</surname><given-names>R</given-names></name><name><surname>Clark</surname><given-names>CM</given-names></name><etal/></person-group><article-title>High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype</article-title><source>Arch Neurol</source><year>1998</year><volume>55</volume><issue>7</issue><fpage>937</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1001/archneur.55.7.937</pub-id></citation><citation citation-type="display-unstructured">Galasko D, Chang L, Motter R, Clark CM et al (1998) High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55(7):937&#x02013;945 <pub-id pub-id-type="pmid">9678311</pub-id></citation></ref><ref id="CR16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geylis</surname><given-names>V</given-names></name><name><surname>Kourilov</surname><given-names>V</given-names></name><name><surname>Meiner</surname><given-names>Z</given-names></name><name><surname>Nennesmo</surname><given-names>I</given-names></name><etal/></person-group><article-title>Human monoclonal antibodies against amyloid-beta from healthy adults</article-title><source>Neurobiol Aging</source><year>2005</year><volume>26</volume><issue>5</issue><fpage>597</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2004.06.008</pub-id></citation><citation citation-type="display-unstructured">Geylis V, Kourilov V, Meiner Z, Nennesmo I et al (2005) Human monoclonal antibodies against amyloid-beta from healthy adults. Neurobiol Aging 26(5):597&#x02013;606 <pub-id pub-id-type="pmid">15708434</pub-id></citation></ref><ref id="CR17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giedraitis</surname><given-names>V</given-names></name><name><surname>Sundelof</surname><given-names>J</given-names></name><name><surname>Irizarry</surname><given-names>MC</given-names></name><name><surname>Garevik</surname><given-names>N</given-names></name><etal/></person-group><article-title>The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer&#x02019;s disease</article-title><source>Neurosci Lett</source><year>2007</year><volume>427</volume><issue>3</issue><fpage>127</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2007.09.023</pub-id></citation><citation citation-type="display-unstructured">Giedraitis V, Sundelof J, Irizarry MC, Garevik N et al (2007) The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer&#x02019;s disease. Neurosci Lett 427(3):127&#x02013;131 <pub-id pub-id-type="pmid">17936506</pub-id></citation></ref><ref id="CR18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graff-Radford</surname><given-names>NR</given-names></name><name><surname>Crook</surname><given-names>JE</given-names></name><name><surname>Lucas</surname><given-names>J</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><etal/></person-group><article-title>Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease</article-title><source>Arch Neurol</source><year>2007</year><volume>64</volume><issue>3</issue><fpage>354</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1001/archneur.64.3.354</pub-id></citation><citation citation-type="display-unstructured">Graff-Radford NR, Crook JE, Lucas J, Boeve BF et al (2007) Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64(3):354&#x02013;362 <pub-id pub-id-type="pmid">17353377</pub-id></citation></ref><ref id="CR19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gruden</surname><given-names>MA</given-names></name><name><surname>Davudova</surname><given-names>TB</given-names></name><name><surname>Malisauskas</surname><given-names>M</given-names></name><name><surname>Zamotin</surname><given-names>VV</given-names></name><etal/></person-group><article-title>Autoimmune responses to amyloid structures of Abeta(25&#x02013;35) peptide and human lysozyme in the serum of patients with progressive Alzheimer&#x02019;s disease</article-title><source>Dement Geriatr Cogn Disord</source><year>2004</year><volume>18</volume><issue>2</issue><fpage>165</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1159/000079197</pub-id></citation><citation citation-type="display-unstructured">Gruden MA, Davudova TB, Malisauskas M, Zamotin VV et al (2004) Autoimmune responses to amyloid structures of Abeta(25&#x02013;35) peptide and human lysozyme in the serum of patients with progressive Alzheimer&#x02019;s disease. Dement Geriatr Cogn Disord 18(2):165&#x02013;171 <pub-id pub-id-type="pmid">15211072</pub-id></citation></ref><ref id="CR20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gruden</surname><given-names>MA</given-names></name><name><surname>Davidova</surname><given-names>TB</given-names></name><name><surname>Malisauskas</surname><given-names>M</given-names></name><name><surname>Sewell</surname><given-names>RD</given-names></name><etal/></person-group><article-title>Differential neuroimmune markers to the onset of Alzheimer&#x02019;s disease neurodegeneration and dementia: autoantibodies to Abeta(25&#x02013;35) oligomers, S100b and neurotransmitters</article-title><source>J Neuroimmunol</source><year>2007</year><volume>186</volume><issue>1&#x02013;2</issue><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2007.03.023</pub-id></citation><citation citation-type="display-unstructured">Gruden MA, Davidova TB, Malisauskas M, Sewell RD et al (2007) Differential neuroimmune markers to the onset of Alzheimer&#x02019;s disease neurodegeneration and dementia: autoantibodies to Abeta(25&#x02013;35) oligomers, S100b and neurotransmitters. J Neuroimmunol 186(1&#x02013;2):181&#x02013;192 <pub-id pub-id-type="pmid">17477976</pub-id></citation></ref><ref id="CR21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>The amyloid hypothesis of Alzheimer&#x02019;s disease: progress and problems on the road to therapeutics</article-title><source>Science</source><year>2002</year><volume>297</volume><issue>5580</issue><fpage>353</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1126/science.1072994</pub-id></citation><citation citation-type="display-unstructured">Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer&#x02019;s disease: progress and problems on the road to therapeutics. Science 297(5580):353&#x02013;356 <pub-id pub-id-type="pmid">12130773</pub-id></citation></ref><ref id="CR22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hock</surname><given-names>C</given-names></name><name><surname>Konietzko</surname><given-names>U</given-names></name><name><surname>Streffer</surname><given-names>JR</given-names></name><name><surname>Tracy</surname><given-names>J</given-names></name><etal/></person-group><article-title>Antibodies against beta-amyloid slow cognitive decline in Alzheimer&#x02019;s disease</article-title><source>Neuron</source><year>2003</year><volume>38</volume><issue>4</issue><fpage>547</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(03)00294-0</pub-id></citation><citation citation-type="display-unstructured">Hock C, Konietzko U, Streffer JR, Tracy J et al (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer&#x02019;s disease. Neuron 38(4):547&#x02013;554 <pub-id pub-id-type="pmid">12765607</pub-id></citation></ref><ref id="CR23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Buldyrev</surname><given-names>I</given-names></name><name><surname>Whelan</surname><given-names>C</given-names></name><etal/></person-group><article-title>Autoantibodies to amyloid-beta and Alzheimer&#x02019;s disease</article-title><source>Ann Neurol</source><year>2001</year><volume>49</volume><issue>6</issue><fpage>808</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1002/ana.1061</pub-id></citation><citation citation-type="display-unstructured">Hyman BT, Smith C, Buldyrev I, Whelan C et al (2001) Autoantibodies to amyloid-beta and Alzheimer&#x02019;s disease. Ann Neurol 49(6):808&#x02013;810 <pub-id pub-id-type="pmid">11409436</pub-id></citation></ref><ref id="CR24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>M</given-names></name><name><surname>Schroder</surname><given-names>J</given-names></name><name><surname>Blomberg</surname><given-names>M</given-names></name><name><surname>Engvall</surname><given-names>B</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer&#x02019;s disease and declines with disease progression</article-title><source>Ann Neurol</source><year>1999</year><volume>45</volume><issue>4</issue><fpage>504</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1002/1531-8249(199904)45:4&#x0003c;504::AID-ANA12&#x0003e;3.0.CO;2-9</pub-id></citation><citation citation-type="display-unstructured">Jensen M, Schroder J, Blomberg M, Engvall B et al (1999) Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer&#x02019;s disease and declines with disease progression. Ann Neurol 45(4):504&#x02013;511 <pub-id pub-id-type="pmid">10211475</pub-id></citation></ref><ref id="CR25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kanai</surname><given-names>M</given-names></name><name><surname>Matsubara</surname><given-names>E</given-names></name><name><surname>Isoe</surname><given-names>K</given-names></name><name><surname>Urakami</surname><given-names>K</given-names></name><etal/></person-group><article-title>Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer&#x02019;s disease: a study in Japan</article-title><source>Ann Neurol</source><year>1998</year><volume>44</volume><issue>1</issue><fpage>17</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1002/ana.410440108</pub-id></citation><citation citation-type="display-unstructured">Kanai M, Matsubara E, Isoe K, Urakami K et al (1998) Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer&#x02019;s disease: a study in Japan. Ann Neurol 44(1):17&#x02013;26 <pub-id pub-id-type="pmid">9667589</pub-id></citation></ref><ref id="CR26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawarabayashi</surname><given-names>T</given-names></name><name><surname>Shoji</surname><given-names>M</given-names></name></person-group><article-title>Plasma biomarkers of Alzheimer&#x02019;s disease</article-title><source>Curr Opin Psychiatry</source><year>2008</year><volume>21</volume><issue>3</issue><fpage>260</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1097/YCO.0b013e3282fc989f</pub-id></citation><citation citation-type="display-unstructured">Kawarabayashi T, Shoji M (2008) Plasma biomarkers of Alzheimer&#x02019;s disease. Curr Opin Psychiatry 21(3):260&#x02013;267 <pub-id pub-id-type="pmid">18382225</pub-id></citation></ref><ref id="CR27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>H</given-names></name><name><surname>Pajonk</surname><given-names>FG</given-names></name><name><surname>Bach</surname><given-names>D</given-names></name><name><surname>Schneider-Axmann</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effect of copper intake on CSF parameters in patients with mild Alzheimer&#x02019;s disease: a pilot phase 2 clinical trial</article-title><source>J Neural Transm</source><year>2008</year><volume>115</volume><issue>12</issue><fpage>1651</fpage><lpage>1659</lpage><pub-id pub-id-type="doi">10.1007/s00702-008-0136-2</pub-id></citation><citation citation-type="display-unstructured">Kessler H, Pajonk FG, Bach D, Schneider-Axmann T et al (2008) Effect of copper intake on CSF parameters in patients with mild Alzheimer&#x02019;s disease: a pilot phase 2 clinical trial. J Neural Transm 115(12):1651&#x02013;1659 <pub-id pub-id-type="pmid">18972062</pub-id></citation></ref><ref id="CR28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kosaka</surname><given-names>T</given-names></name><name><surname>Imagawa</surname><given-names>M</given-names></name><name><surname>Seki</surname><given-names>K</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name><etal/></person-group><article-title>The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43)</article-title><source>Neurology</source><year>1997</year><volume>48</volume><issue>3</issue><fpage>741</fpage><lpage>745</lpage></citation><citation citation-type="display-unstructured">Kosaka T, Imagawa M, Seki K, Arai H et al (1997) The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology 48(3):741&#x02013;745 <pub-id pub-id-type="pmid">9065558</pub-id></citation></ref><ref id="CR29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>YM</given-names></name><name><surname>Kokjohn</surname><given-names>TA</given-names></name><name><surname>Kalback</surname><given-names>W</given-names></name><name><surname>Luehrs</surname><given-names>D</given-names></name><etal/></person-group><article-title>Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma</article-title><source>Biochem Biophys Res Commun</source><year>2000</year><volume>268</volume><issue>3</issue><fpage>750</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2000.2222</pub-id></citation><citation citation-type="display-unstructured">Kuo YM, Kokjohn TA, Kalback W, Luehrs D et al (2000a) Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun 268(3):750&#x02013;756 <pub-id pub-id-type="pmid">10679277</pub-id></citation></ref><ref id="CR30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>YM</given-names></name><name><surname>Kokjohn</surname><given-names>TA</given-names></name><name><surname>Kalback</surname><given-names>W</given-names></name><name><surname>Luehrs</surname><given-names>D</given-names></name><etal/></person-group><article-title>Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma</article-title><source>Biochem Biophys Res Commun</source><year>2000</year><volume>268</volume><issue>3</issue><fpage>750</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2000.2222</pub-id></citation><citation citation-type="display-unstructured">Kuo YM, Kokjohn TA, Kalback W, Luehrs D et al (2000b) Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun 268(3):750&#x02013;756 <pub-id pub-id-type="pmid">10679277</pub-id></citation></ref><ref id="CR31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewczuk</surname><given-names>P</given-names></name><name><surname>Esselmann</surname><given-names>H</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name><name><surname>Maler</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Neurochemical diagnosis of Alzheimer&#x02019;s dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau</article-title><source>Neurobiol Aging</source><year>2004</year><volume>25</volume><issue>3</issue><fpage>273</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/S0197-4580(03)00086-1</pub-id></citation><citation citation-type="display-unstructured">Lewczuk P, Esselmann H, Otto M, Maler JM et al (2004) Neurochemical diagnosis of Alzheimer&#x02019;s dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging 25(3):273&#x02013;281 <pub-id pub-id-type="pmid">15123331</pub-id></citation></ref><ref id="CR32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsubara</surname><given-names>E</given-names></name><name><surname>Ghiso</surname><given-names>J</given-names></name><name><surname>Frangione</surname><given-names>B</given-names></name><name><surname>Amari</surname><given-names>M</given-names></name><etal/></person-group><article-title>Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer&#x02019;s disease and Down&#x02019;s syndrome</article-title><source>Ann Neurol</source><year>1999</year><volume>45</volume><issue>4</issue><fpage>537</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1002/1531-8249(199904)45:4&#x0003c;537::AID-ANA20&#x0003e;3.0.CO;2-2</pub-id></citation><citation citation-type="display-unstructured">Matsubara E, Ghiso J, Frangione B, Amari M et al (1999) Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer&#x02019;s disease and Down&#x02019;s syndrome. Ann Neurol 45(4):537&#x02013;541 <pub-id pub-id-type="pmid">10211483</pub-id></citation></ref><ref id="CR33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Yanase</surname><given-names>D</given-names></name><name><surname>Noguchi-Shinohara</surname><given-names>M</given-names></name><name><surname>Ono</surname><given-names>K</given-names></name><etal/></person-group><article-title>Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood&#x02013;brain barrier in Alzheimer&#x02019;s disease</article-title><source>Dement Geriatr Cogn Disord</source><year>2007</year><volume>23</volume><issue>4</issue><fpage>241</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1159/000100019</pub-id></citation><citation citation-type="display-unstructured">Matsumoto Y, Yanase D, Noguchi-Shinohara M, Ono K et al (2007) Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood&#x02013;brain barrier in Alzheimer&#x02019;s disease. Dement Geriatr Cogn Disord 23(4):241&#x02013;245 <pub-id pub-id-type="pmid">17310121</pub-id></citation></ref><ref id="CR34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McGeer</surname><given-names>PL</given-names></name><name><surname>McGeer</surname><given-names>EG</given-names></name></person-group><article-title>Inflammation, autotoxicity and Alzheimer disease</article-title><source>Neurobiol Aging</source><year>2001</year><volume>22</volume><issue>6</issue><fpage>799</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1016/S0197-4580(01)00289-5</pub-id></citation><citation citation-type="display-unstructured">McGeer PL, McGeer EG (2001) Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 22(6):799&#x02013;809 <pub-id pub-id-type="pmid">11754986</pub-id></citation></ref><ref id="CR35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><etal/></person-group><article-title>Clinical diagnosis of Alzheimer&#x02019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x02019;s Disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><issue>7</issue><fpage>939</fpage><lpage>944</lpage></citation><citation citation-type="display-unstructured">McKhann G, Drachman D, Folstein M, Katzman R et al (1984) Clinical diagnosis of Alzheimer&#x02019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x02019;s Disease. Neurology 34(7):939&#x02013;944 <pub-id pub-id-type="pmid">6610841</pub-id></citation></ref><ref id="CR36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>PD</given-names></name><name><surname>Pirttila</surname><given-names>T</given-names></name></person-group><article-title>Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer disease</article-title><source>Neurodegener Dis</source><year>2005</year><volume>2</volume><issue>5</issue><fpage>242</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1159/000090363</pub-id></citation><citation citation-type="display-unstructured">Mehta PD, Pirttila T (2005) Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer disease. Neurodegener Dis 2(5):242&#x02013;245 <pub-id pub-id-type="pmid">16909004</pub-id></citation></ref><ref id="CR37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>PD</given-names></name><name><surname>Pirttila</surname><given-names>T</given-names></name><name><surname>Mehta</surname><given-names>SP</given-names></name><name><surname>Sersen</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease</article-title><source>Arch Neurol</source><year>2000</year><volume>57</volume><issue>1</issue><fpage>100</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1001/archneur.57.1.100</pub-id></citation><citation citation-type="display-unstructured">Mehta PD, Pirttila T, Mehta SP, Sersen EA et al (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57(1):100&#x02013;105 <pub-id pub-id-type="pmid">10634455</pub-id></citation></ref><ref id="CR38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>PD</given-names></name><name><surname>Pirttila</surname><given-names>T</given-names></name><name><surname>Patrick</surname><given-names>BA</given-names></name><name><surname>Barshatzky</surname><given-names>M</given-names></name><etal/></person-group><article-title>Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease</article-title><source>Neurosci Lett</source><year>2001</year><volume>304</volume><issue>1&#x02013;2</issue><fpage>102</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(01)01754-2</pub-id></citation><citation citation-type="display-unstructured">Mehta PD, Pirttila T, Patrick BA, Barshatzky M et al (2001) Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 304(1&#x02013;2):102&#x02013;106 <pub-id pub-id-type="pmid">11335065</pub-id></citation></ref><ref id="CR39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Hall</surname><given-names>E</given-names></name><name><surname>Tuzova</surname><given-names>M</given-names></name><name><surname>Dobbs</surname><given-names>M</given-names></name><etal/></person-group><article-title>Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer&#x02019;s disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development</article-title><source>Neuromolecular Med</source><year>2003</year><volume>3</volume><issue>1</issue><fpage>29</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1385/NMM:3:1:29</pub-id></citation><citation citation-type="display-unstructured">Nath A, Hall E, Tuzova M, Dobbs M et al (2003) Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer&#x02019;s disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med 3(1):29&#x02013;39 <pub-id pub-id-type="pmid">12665674</pub-id></citation></ref><ref id="CR40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nydegger</surname><given-names>UE</given-names></name></person-group><article-title>Immune complex pathophysiology</article-title><source>Ann N Y Acad Sci</source><year>2007</year><volume>1109</volume><fpage>66</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1196/annals.1398.009</pub-id></citation><citation citation-type="display-unstructured">Nydegger UE (2007) Immune complex pathophysiology. Ann N Y Acad Sci 1109:66&#x02013;83 <pub-id pub-id-type="pmid">17785292</pub-id></citation></ref><ref id="CR41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pesaresi</surname><given-names>M</given-names></name><name><surname>Lovati</surname><given-names>C</given-names></name><name><surname>Bertora</surname><given-names>P</given-names></name><name><surname>Mailland</surname><given-names>E</given-names></name><etal/></person-group><article-title>Plasma levels of beta-amyloid (1-42) in Alzheimer&#x02019;s disease and mild cognitive impairment</article-title><source>Neurobiol Aging</source><year>2006</year><volume>27</volume><issue>6</issue><fpage>904</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2006.03.004</pub-id></citation><citation citation-type="display-unstructured">Pesaresi M, Lovati C, Bertora P, Mailland E et al (2006) Plasma levels of beta-amyloid (1-42) in Alzheimer&#x02019;s disease and mild cognitive impairment. Neurobiol Aging 27(6):904&#x02013;905 <pub-id pub-id-type="pmid">16638622</pub-id></citation></ref><ref id="CR42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pomara</surname><given-names>N</given-names></name><name><surname>Willoughby</surname><given-names>LM</given-names></name><name><surname>Sidtis</surname><given-names>JJ</given-names></name><name><surname>Mehta</surname><given-names>PD</given-names></name></person-group><article-title>Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report</article-title><source>Am J Geriatr Psychiatry</source><year>2005</year><volume>13</volume><issue>10</issue><fpage>914</fpage><lpage>917</lpage></citation><citation citation-type="display-unstructured">Pomara N, Willoughby LM, Sidtis JJ, Mehta PD (2005) Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am J Geriatr Psychiatry 13(10):914&#x02013;917 <pub-id pub-id-type="pmid">16223971</pub-id></citation></ref><ref id="CR43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>JL</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name></person-group><article-title>Tangles and plaques in nondemented aging and &#x0201c;preclinical&#x0201d; Alzheimer&#x02019;s disease</article-title><source>Ann Neurol</source><year>1999</year><volume>45</volume><issue>3</issue><fpage>358</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1002/1531-8249(199903)45:3&#x0003c;358::AID-ANA12&#x0003e;3.0.CO;2-X</pub-id></citation><citation citation-type="display-unstructured">Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and &#x0201c;preclinical&#x0201d; Alzheimer&#x02019;s disease. Ann Neurol 45(3):358&#x02013;368 <pub-id pub-id-type="pmid">10072051</pub-id></citation></ref><ref id="CR44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>VK</given-names></name></person-group><article-title>Neuroautoimmunity: pathogenic implications for Alzheimer&#x02019;s disease</article-title><source>Gerontology</source><year>1997</year><volume>43</volume><issue>1&#x02013;2</issue><fpage>79</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1159/000213837</pub-id></citation><citation citation-type="display-unstructured">Singh VK (1997) Neuroautoimmunity: pathogenic implications for Alzheimer&#x02019;s disease. Gerontology 43(1&#x02013;2):79&#x02013;94 <pub-id pub-id-type="pmid">8996831</pub-id></citation></ref><ref id="CR45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sundelof</surname><given-names>J</given-names></name><name><surname>Giedraitis</surname><given-names>V</given-names></name><name><surname>Irizarry</surname><given-names>MC</given-names></name><name><surname>Sundstrom</surname><given-names>J</given-names></name><etal/></person-group><article-title>Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study</article-title><source>Arch Neurol</source><year>2008</year><volume>65</volume><issue>2</issue><fpage>256</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2007.57</pub-id></citation><citation citation-type="display-unstructured">Sundelof J, Giedraitis V, Irizarry MC, Sundstrom J et al (2008) Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol 65(2):256&#x02013;263 <pub-id pub-id-type="pmid">18268197</pub-id></citation></ref><ref id="CR46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>N</given-names></name><name><surname>Cheung</surname><given-names>TT</given-names></name><name><surname>Cai</surname><given-names>X-D</given-names></name><name><surname>Odaka</surname><given-names>A</given-names></name><etal/></person-group><article-title>An increased percentage of long amyloid &#x003b2; protein is secreated by familial amyloid &#x003b2; protein precursor (&#x003b2;APP717) mutants</article-title><source>Science</source><year>1994</year><volume>264</volume><fpage>1336</fpage><lpage>1340</lpage><pub-id pub-id-type="doi">10.1126/science.8191290</pub-id></citation><citation citation-type="display-unstructured">Suzuki N, Cheung TT, Cai X-D, Odaka A et al (1994) An increased percentage of long amyloid &#x003b2; protein is secreated by familial amyloid &#x003b2; protein precursor (&#x003b2;APP717) mutants. Science 264:1336&#x02013;1340 <pub-id pub-id-type="pmid">8191290</pub-id></citation></ref><ref id="CR47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tamaoka</surname><given-names>A</given-names></name><name><surname>Fukushima</surname><given-names>T</given-names></name><name><surname>Sawamura</surname><given-names>N</given-names></name><name><surname>Ishikawa</surname><given-names>K</given-names></name><etal/></person-group><article-title>Amyloid beta protein in plasma from patients with sporadic Alzheimer&#x02019;s disease</article-title><source>J Neurol Sci</source><year>1996</year><volume>141</volume><issue>1&#x02013;2</issue><fpage>65</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/0022-510X(96)00143-8</pub-id></citation><citation citation-type="display-unstructured">Tamaoka A, Fukushima T, Sawamura N, Ishikawa K et al (1996) Amyloid beta protein in plasma from patients with sporadic Alzheimer&#x02019;s disease. J Neurol Sci 141(1&#x02013;2):65&#x02013;68 <pub-id pub-id-type="pmid">8880695</pub-id></citation></ref><ref id="CR48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tapiola</surname><given-names>T</given-names></name><name><surname>Pirttila</surname><given-names>T</given-names></name><name><surname>Mehta</surname><given-names>PD</given-names></name><name><surname>Alafuzofff</surname><given-names>I</given-names></name><etal/></person-group><article-title>Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer&#x02019;s disease</article-title><source>Neurobiol Aging</source><year>2000</year><volume>21</volume><issue>5</issue><fpage>735</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1016/S0197-4580(00)00164-0</pub-id></citation><citation citation-type="display-unstructured">Tapiola T, Pirttila T, Mehta PD, Alafuzofff I et al (2000) Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer&#x02019;s disease. Neurobiol Aging 21(5):735&#x02013;740 <pub-id pub-id-type="pmid">11016543</pub-id></citation></ref><ref id="CR49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tarkowski</surname><given-names>E</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Tarkowski</surname><given-names>A</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name></person-group><article-title>Intrathecal inflammation precedes development of Alzheimer&#x02019;s disease</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2003</year><volume>74</volume><issue>9</issue><fpage>1200</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1136/jnnp.74.9.1200</pub-id></citation><citation citation-type="display-unstructured">Tarkowski E, Andreasen N, Tarkowski A, Blennow K (2003) Intrathecal inflammation precedes development of Alzheimer&#x02019;s disease. J Neurol Neurosurg Psychiatry 74(9):1200&#x02013;1205 <pub-id pub-id-type="pmid">12933918</pub-id></citation></ref><ref id="CR50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trieb</surname><given-names>K</given-names></name><name><surname>Ransmayr</surname><given-names>G</given-names></name><name><surname>Sgonc</surname><given-names>R</given-names></name><name><surname>Lassmann</surname><given-names>H</given-names></name><etal/></person-group><article-title>APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer&#x02019;s disease</article-title><source>Neurobiol Aging</source><year>1996</year><volume>17</volume><issue>4</issue><fpage>541</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1016/0197-4580(96)00068-1</pub-id></citation><citation citation-type="display-unstructured">Trieb K, Ransmayr G, Sgonc R, Lassmann H et al (1996) APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer&#x02019;s disease. Neurobiol Aging 17(4):541&#x02013;547 <pub-id pub-id-type="pmid">8832628</pub-id></citation></ref><ref id="CR51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Growdon</surname><given-names>JH</given-names></name></person-group><article-title>A new consensus report on biomarkers for the early antemortem diagnosis of Alzheimer disease: current status, relevance to drug discovery, and recommendations for future research</article-title><source>J Neuropathol Exp Neurol</source><year>1998</year><volume>57</volume><issue>6</issue><fpage>643</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1097/00005072-199806000-00010</pub-id></citation><citation citation-type="display-unstructured">Trojanowski JQ, Growdon JH (1998) A new consensus report on biomarkers for the early antemortem diagnosis of Alzheimer disease: current status, relevance to drug discovery, and recommendations for future research. J Neuropathol Exp Neurol 57(6):643&#x02013;644 <pub-id pub-id-type="pmid">9630242</pub-id></citation></ref><ref id="CR52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oijen</surname><given-names>M</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Soares</surname><given-names>HD</given-names></name><name><surname>Koudstaal</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case&#x02013;cohort study</article-title><source>Lancet Neurol</source><year>2006</year><volume>5</volume><issue>8</issue><fpage>655</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(06)70501-4</pub-id></citation><citation citation-type="display-unstructured">van Oijen M, Hofman A, Soares HD, Koudstaal PJ et al (2006) Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case&#x02013;cohort study. Lancet Neurol 5(8):655&#x02013;660 <pub-id pub-id-type="pmid">16857570</pub-id></citation></ref><ref id="CR53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vanderstichele</surname><given-names>H</given-names></name><name><surname>Kerschaver</surname><given-names>E</given-names></name><name><surname>Hesse</surname><given-names>C</given-names></name><name><surname>Davidsson</surname><given-names>P</given-names></name><etal/></person-group><article-title>Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma</article-title><source>Amyloid</source><year>2000</year><volume>7</volume><issue>4</issue><fpage>245</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.3109/13506120009146438</pub-id></citation><citation citation-type="display-unstructured">Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P et al (2000) Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7(4):245&#x02013;258 <pub-id pub-id-type="pmid">11132093</pub-id></citation></ref><ref id="CR54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weksler</surname><given-names>ME</given-names></name><name><surname>Relkin</surname><given-names>N</given-names></name><name><surname>Turkenich</surname><given-names>R</given-names></name><name><surname>LaRusse</surname><given-names>S</given-names></name><etal/></person-group><article-title>Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals</article-title><source>Exp Gerontol</source><year>2002</year><volume>37</volume><issue>7</issue><fpage>943</fpage><lpage>948</lpage></citation><citation citation-type="display-unstructured">Weksler ME, Relkin N, Turkenich R, LaRusse S et al (2002) Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 37(7):943&#x02013;948 <pub-id pub-id-type="pmid">12086704</pub-id></citation></ref><ref id="CR55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Palmer</surname><given-names>K</given-names></name><name><surname>Kivipelto</surname><given-names>M</given-names></name><name><surname>Jelic</surname><given-names>V</given-names></name><etal/></person-group><article-title>Mild cognitive impairment&#x02014;beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment</article-title><source>J Intern Med</source><year>2004</year><volume>256</volume><issue>3</issue><fpage>240</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2796.2004.01380.x</pub-id></citation><citation citation-type="display-unstructured">Winblad B, Palmer K, Kivipelto M, Jelic V et al (2004) Mild cognitive impairment&#x02014;beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256(3):240&#x02013;246 <pub-id pub-id-type="pmid">15324367</pub-id></citation></ref><ref id="CR56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woulfe</surname><given-names>JM</given-names></name><name><surname>Duke</surname><given-names>R</given-names></name><name><surname>Middeldorp</surname><given-names>JM</given-names></name><name><surname>Stevens</surname><given-names>S</given-names></name><etal/></person-group><article-title>Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane protein antibodies in PD</article-title><source>Neurology</source><year>2002</year><volume>58</volume><issue>9</issue><fpage>1435</fpage><lpage>1436</lpage></citation><citation citation-type="display-unstructured">Woulfe JM, Duke R, Middeldorp JM, Stevens S et al (2002) Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane protein antibodies in PD. Neurology 58(9):1435&#x02013;1436 <pub-id pub-id-type="pmid">12011302</pub-id></citation></ref><ref id="CR57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Gaskin</surname><given-names>F</given-names></name></person-group><article-title>Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer&#x02019;s disease</article-title><source>Mech Ageing Dev</source><year>1997</year><volume>94</volume><issue>1&#x02013;3</issue><fpage>213</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/S0047-6374(96)01861-1</pub-id></citation><citation citation-type="display-unstructured">Xu S, Gaskin F (1997) Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer&#x02019;s disease. Mech Ageing Dev 94(1&#x02013;3):213&#x02013;222 <pub-id pub-id-type="pmid">9147373</pub-id></citation></ref><ref id="CR58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Kawarabayashi</surname><given-names>T</given-names></name><name><surname>Matsubara</surname><given-names>E</given-names></name><name><surname>Deguchi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer&#x02019;s disease and normal controls</article-title><source>Brain Res</source><year>2008</year><volume>1219</volume><fpage>169</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2008.02.060</pub-id></citation><citation citation-type="display-unstructured">Xu W, Kawarabayashi T, Matsubara E, Deguchi K et al (2008) Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer&#x02019;s disease and normal controls. Brain Res 1219:169&#x02013;179 <pub-id pub-id-type="pmid">18534566</pub-id></citation></ref><ref id="CR59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Sugihara</surname><given-names>S</given-names></name><name><surname>Ogawa</surname><given-names>A</given-names></name><name><surname>Oshima</surname><given-names>N</given-names></name><etal/></person-group><article-title>Alzheimer beta amyloid deposition enhanced by apoE epsilon4 gene precedes neurofibrillary pathology in the frontal association cortex of nondemented senior subjects</article-title><source>J Neuropathol Exp Neurol</source><year>2001</year><volume>60</volume><issue>7</issue><fpage>731</fpage><lpage>739</lpage></citation><citation citation-type="display-unstructured">Yamaguchi H, Sugihara S, Ogawa A, Oshima N et al (2001) Alzheimer beta amyloid deposition enhanced by apoE epsilon4 gene precedes neurofibrillary pathology in the frontal association cortex of nondemented senior subjects. J Neuropathol Exp Neurol 60(7):731&#x02013;739 <pub-id pub-id-type="pmid">11444802</pub-id></citation></ref></ref-list></back></article> 